Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Xuefeng Zhang; Jing Wang; Jing Lu; Rongrong Li; Shuli Zhao

doi:10.1186/s12985-018-1049-9

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Virol J. 2018 Sep 3;15(1):137. doi: 10.1186/s12985-018-1049-9.

Authors

Xuefeng Zhang¹, Jing Wang¹, Jing Lu¹, Rongrong Li¹, Shuli Zhao^{2

3}

Affiliations

¹ Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing, 211800, China.
² Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing, 211800, China. shulizhao79@163.com.
³ Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China. shulizhao79@163.com.

Abstract

Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.

Publication types

Published Erratum